WO2012118349A3 - 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 - Google Patents

제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 Download PDF

Info

Publication number
WO2012118349A3
WO2012118349A3 PCT/KR2012/001587 KR2012001587W WO2012118349A3 WO 2012118349 A3 WO2012118349 A3 WO 2012118349A3 KR 2012001587 W KR2012001587 W KR 2012001587W WO 2012118349 A3 WO2012118349 A3 WO 2012118349A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
natural killer
positive
cord blood
differentiation
Prior art date
Application number
PCT/KR2012/001587
Other languages
English (en)
French (fr)
Other versions
WO2012118349A9 (ko
WO2012118349A2 (ko
Inventor
최인표
윤석란
김미정
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2012118349A2 publication Critical patent/WO2012118349A2/ko
Publication of WO2012118349A9 publication Critical patent/WO2012118349A9/ko
Publication of WO2012118349A3 publication Critical patent/WO2012118349A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 제대혈로부터 효율적인 자연살해세포(natural killer cell; NK 세포)의 증식 및 분화 방법에 관한 것으로, 보다 상세하게는 1) 제대혈 유래 단핵세포로부터 CD3, CD34, CD56 및 CD19 양성세포를 제거하여 CD3-CD34-CD56-CD19-세포를 제조하는 단계; 2) 상기 CD3-CD34-CD56-CD19-세포로부터 CD14 음성세포를 제거하여 CD3-CD34-CD56-CD19-CD14+세포를 제조하는 단계; 및 3) 상기 CD3-CD34-CD56-CD19-CD14+세포에 IL-15 및 IL-21을 혼합처리한 후 배양하는 단계를 포함하는 제대혈로부터 효율적으로 자연살해세포를 증식 및 분화시키는 방법에 관한 것이다. 본 발명은 CD14 양성세포로부터 NK 세포를 유도함으로써 조혈 줄기 세포로부터 NK 세포를 유도하는 방법에 비해 순도가 높은 NK 세포를 단시간에 얻을 수 있고, 또한 우수한 세포 살상능 활성을 가진 NK 세포를 단시간에 유도하여 암세포 살상 기능이 있는 NK 세포를 분화시킬 수 있으므로 항암세포 치료에 유용하게 이용될 수 있다.
PCT/KR2012/001587 2011-03-03 2012-03-02 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 WO2012118349A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0018949 2011-03-03
KR1020110018949A KR101447546B1 (ko) 2011-03-03 2011-03-03 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법

Publications (3)

Publication Number Publication Date
WO2012118349A2 WO2012118349A2 (ko) 2012-09-07
WO2012118349A9 WO2012118349A9 (ko) 2012-10-11
WO2012118349A3 true WO2012118349A3 (ko) 2012-11-29

Family

ID=46758394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001587 WO2012118349A2 (ko) 2011-03-03 2012-03-02 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법

Country Status (2)

Country Link
KR (1) KR101447546B1 (ko)
WO (1) WO2012118349A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3114215B1 (en) * 2014-03-07 2021-04-14 Emercell SAS Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
WO2017003153A1 (ko) * 2015-06-29 2017-01-05 주식회사 녹십자랩셀 제대혈 단핵세포 또는 이로부터 유래된 세포로부터 자연살해세포를 제조하는 방법
KR20230078541A (ko) 2021-11-23 2023-06-02 재단법인 아산사회복지재단 이중특이성항체를 이용한 자연살해세포 대량증식 방법
CN114058584B (zh) * 2022-01-07 2022-07-01 山东省齐鲁干细胞工程有限公司 一种临床用自然杀伤细胞的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100045704A (ko) * 2008-10-24 2010-05-04 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100045704A (ko) * 2008-10-24 2010-05-04 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DALLE ET AL.: "Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections", PEDIATRIC RESEARCH, vol. 57, no. 5, 2005, pages 649 - 655 *
GIULIANI ET AL.: "Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15", PLOS ONE, vol. 3, no. ISSUE, 21 May 2008 (2008-05-21), pages 1 - 16 *
STRENGELL ET AL.: "IL-21 in synergy with IL-15 or IL-18 enhance IFN-gamma production in human NK an T cells", THE JOURNAL OF IMMUNOLOGY, vol. 170, 2003, pages 5464 - 5469 *

Also Published As

Publication number Publication date
WO2012118349A9 (ko) 2012-10-11
KR20120100207A (ko) 2012-09-12
KR101447546B1 (ko) 2014-10-08
WO2012118349A2 (ko) 2012-09-07

Similar Documents

Publication Publication Date Title
WO2010047475A3 (ko) 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
EA201890996A1 (ru) Способ получения t-клеток для т-клеточной терапии
SI2752484T1 (en) A method for preparing a basic medium for mesenchymal stem cells, a basic medium for mesenchymal stem cells and a cell therapeutic agent, cultured and differentiated using it
MX2018011791A (es) Compuestos para transduccion viral mejorada.
EP2782996A4 (en) POPULATIONS OF HEMATOPOETIC PROCEDURES AND METHOD FOR ENRICHING STEM CELLS THEREFOR
WO2012019103A3 (en) System and apparatus for cell treatment
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
MY180625A (en) Algal lipid compositions and methods of preparing and utilizing the same
MY181513A (en) Cell culture compositions and methods for polypeptide production
WO2012118349A3 (ko) 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
MX2014002087A (es) Formulaciones piretroides.
WO2011096728A3 (en) Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling
WO2013093919A3 (en) A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion
EP3722320A3 (en) Anti-complement c1s antibodies and uses thereof
IN2015DN01737A (ko)
WO2012012737A3 (en) Stable tregs and related materials and methods
WO2011099783A3 (ko) 지방조직 유래 줄기세포 및 단핵구로부터 세포성장인자의 생산방법 및 그 이용
EP2591090A4 (en) CERAMIC LIKE GLYCOLIPIDE ASSOCIATED BACTERIAL VACCINES AND USES THEREOF
MX352461B (es) Metodos para la preparacion de hidrogeles usando enzimas de lipasas.
WO2010092571A3 (en) Short beta-defensin-derived peptides
WO2006102209A3 (en) Cd34(+) cells and their methods of use
WO2009155041A3 (en) Method to modulate hematopoietic stem cell growth
RU2012148391A (ru) СПОСОБЫ ИДЕНТИФИКАЦИИ, ВЫДЕЛЕНИЯ, ИСТОЩЕНИЯ И ОБОГАЩЕНИЯ ПОПУЛЯЦИЙ Tr1 КЛЕТОК, ПОПУЛЯЦИИ Tr1 КЛЕТОК, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБ МОНИТОРИНГА ЭФФЕКТА ТЕРАПИИ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12752280

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12752280

Country of ref document: EP

Kind code of ref document: A2